Copyright
©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1468-1480
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1468
Table 3 Median progression-free survival and overall survival in the subgroup analyses
| Survival rate | Low BMI | Normal BMI | Smoking | Non-smoking | Alcohol | No alcohol |
| Median progression-free survival | 2 | 3.5 | 2.96 | 4.23 | 3.1 | 3.5 |
| Median overall survival | 4.1 | 7 | 5.47 | 7.79 | 5.8 | 6.8 |
- Citation: Fasano M, Pirozzi M, Vitale P, Damiano V, Ronzino G, Farese S, Carfora V, Ciccarelli G, Di Giovanni I, Facchini S, Cennamo G, Caraglia M, Ciardiello F, Addeo R. Paclitaxel for second-line treatment of squamous cell carcinoma of the head and neck: A multicenter retrospective Italian study. World J Clin Oncol 2024; 15(12): 1468-1480
- URL: https://www.wjgnet.com/2218-4333/full/v15/i12/1468.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i12.1468